

# Charis Pericleous

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1822740/publications.pdf>

Version: 2024-02-01

43  
papers

1,321  
citations

430754

18  
h-index

345118

36  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1304  
citing authors

#	ARTICLE	IF	CITATIONS
1	ORIGINAL ARTICLE: Antiphospholipid Antibodies Induce a Pro-inflammatory Response in First Trimester Trophoblast Via the TLR4/MyD88 Pathway. <i>American Journal of Reproductive Immunology</i> , 2009, 62, 96-111.	1.2	158
2	Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human $\beta_2$ -glycoprotein I: Mutation studies including residues R39 to R43. <i>Arthritis and Rheumatism</i> , 2007, 56, 280-290.	6.7	134
3	In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of $\beta_2$ -glycoprotein I: proof of concept. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 833-842.	1.9	118
4	Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen $\beta_2$ -glycoprotein I. <i>Arthritis and Rheumatism</i> , 2011, 63, 2774-2782.	6.7	96
5	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , 2020, 39, 100610.	2.8	85
6	Effects of Polyclonal IgG Derived from Patients with Different Clinical Types of the Antiphospholipid Syndrome on Monocyte Signaling Pathways. <i>Journal of Immunology</i> , 2010, 184, 6622-6628.	0.4	67
7	Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of $\beta_2$ -glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. <i>Rheumatology</i> , 2015, 54, 722-727.	0.9	67
8	Measuring IgA Anti- $\beta_2$ -Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. <i>PLoS ONE</i> , 2016, 11, e0156407.	1.1	66
9	Modulation of Trophoblast Angiogenic Factor Secretion by Antiphospholipid Antibodies is Not Reversed by Heparin. <i>American Journal of Reproductive Immunology</i> , 2011, 66, 286-296.	1.2	65
10	Antibodies to domain I of $\beta_2$ -glycoprotein I and IgA antiphospholipid antibodies in patients with $\beta_2$ -glycoprotein I seronegative antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 317-319.	0.5	42
11	Purified IgG from Patients with Obstetric but not IgG from Non-obstetric Antiphospholipid Syndrome Inhibit Trophoblast Invasion. <i>American Journal of Reproductive Immunology</i> , 2015, 73, 390-401.	1.2	35
12	Hydroxychloroquine Protects against Cardiac Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation. <i>PLoS ONE</i> , 2015, 10, e0143771.	1.1	27
13	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018, 93, 114-123.	3.0	24
14	Are endothelial microparticles potential markers of vascular dysfunction in the antiphospholipid syndrome?. <i>Lupus</i> , 2009, 18, 671-675.	0.8	22
15	Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2013, 109, 72-78.	1.8	22
16	Longer duration of B cell depletion is associated with better outcome. <i>Rheumatology</i> , 2015, 54, 1876-1881.	0.9	21
17	Antiphospholipid antibodies and neurological manifestations in acute COVID-19: A single-centre cross-sectional study. <i>EClinicalMedicine</i> , 2021, 39, 101070.	3.2	21
18	Thrombin Binding Predicts the Effects of Sequence Changes in a Human Monoclonal Antiphospholipid Antibody on Its In Vivo Biologic Actions. <i>Journal of Immunology</i> , 2009, 182, 4836-4843.	0.4	19

#	ARTICLE	IF	CITATIONS
19	Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. <i>Cell Death and Disease</i> , 2018, 8, e2549-e2549.	2.7	17
20	Evaluating the conformation of recombinant domain I of $\beta_2$ -glycoprotein I and its interaction with human monoclonal antibodies. <i>Molecular Immunology</i> , 2011, 49, 56-63.	1.0	16
21	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. <i>Arthritis Research and Therapy</i> , 2015, 17, 47.	1.6	16
22	Identification of a Novel HIF-1 $\alpha$ - $\beta$ 2 Integrin-NET Axis in Fibrotic Interstitial Lung Disease. <i>Frontiers in Immunology</i> , 2020, 11, 2190.	2.2	16
23	Gene expression studies on bioelectrosprayed primary cardiac myocytes. <i>Biotechnology Journal</i> , 2008, 3, 530-535.	1.8	15
24	Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3512-3521.	6.7	15
25	The association between IgG and IgM antibodies against cardiolipin, $\beta_2$ -glycoprotein I and Domain I of $\beta_2$ -glycoprotein I with disease profile in patients with multiple sclerosis. <i>Molecular Immunology</i> , 2016, 75, 161-167.	1.0	14
26	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 2413.	2.2	14
27	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. <i>Rheumatology</i> , 2020, 59, 146-152.	0.9	14
28	Autoimmune rheumatic disease IgG has differential effects upon neutrophil integrin activation that is modulated by the endothelium. <i>Scientific Reports</i> , 2019, 9, 1283.	1.6	13
29	New therapeutic targets for the antiphospholipid syndrome. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1291-1299.	1.5	11
30	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. <i>Frontiers in Immunology</i> , 2018, 9, 2244.	2.2	11
31	Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?. <i>Rheumatology</i> , 2021, 60, 1376-1386.	0.9	11
32	Domain I: the hidden face of antiphospholipid syndrome. <i>Lupus</i> , 2014, 23, 1320-1323.	0.8	9
33	Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. <i>BMC Biotechnology</i> , 2015, 15, 104.	1.7	8
34	Oxidation of $\beta_2$ -glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. <i>PLoS ONE</i> , 2017, 12, e0186513.	1.1	8
35	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome. <i>Scientific Reports</i> , 2017, 7, 10788.	1.6	7
36	Laboratory Tests for the Antiphospholipid Syndrome. <i>Methods in Molecular Biology</i> , 2014, 1134, 221-235.	0.4	5

#	ARTICLE	IF	CITATIONS
37	Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2014, 16, R48.	1.6	4
38	Do Antiphospholipid Antibodies Have Direct Pathologic Effects Upon Endometrial and Trophoblast Cells?. <i>Current Rheumatology Reviews</i> , 2009, 5, 83-97.	0.4	4
39	Domain I of $\beta$ 2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation. <i>Lupus</i> , 2019, 28, 893-897.	0.8	2
40	O41. Antiphospholipid Antibodies Enhance Cardiomyocyte Apoptosis in A Simulated in Vitro Cardiac Ischaemia/Reperfusion Injury Model: A Process Dependent on the Pro-Apoptotic Kinase P38 Mapk. <i>Rheumatology</i> , 0, , .	0.9	0
41	239. PEGYLATED DOMAIN I OF BETA-2-GLYCOPROTEIN I PREVENTS THROMBOSIS IN A MOUSE MODEL. <i>Rheumatology</i> , 2017, 56, .	0.9	0
42	Meta-Analysis of 19 Clinical Trials using Omega-3 Fatty Acids Indicate Distinct Outcomes for Icosapent Ethyl. <i>Journal of Clinical Lipidology</i> , 2022, 16, e28.	0.6	0
43	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2022, 13, 842923.	2.2	0